4-[[(E)-(3-Pyridinylmethylene)amino]methyl]benzoic acid, 1g

1-[3-[[(2R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[(1E)-2-(phenylsulfonyl)ethenyl]-1H-indol-1-yl]ethanone, 98%, 1g

1,4,7-Triazonane trihydrochloride, 95.0%, 1g

METHYL 4-CHLOROBUTYRATE, 97.0%, 25ml

N-Ethynyl-N,4-dimethylbenzenesulfonamide, 97%, 25g

(2S,3R,4S,5R,6R)-2-((6-fluoro-1H-indol-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, 95+%, 25mg

(4-Ethynylphenyl)boronic acid, 97%, 10g

3-Bromo-3'-chloro-1,1'-biphenyl>98.0%(GC)25g

(E)-N-(2-Chloro-6-methylphenyl)-3-ethoxyacrylamide, 95.0%, 25g

Fase de planificación PLPHi 20x/0,40 objetivo IOS corregido al infinito. Distancia de trabajo 8,80 mm

Ethyl 5-cyanonicotinate, 97%, 250mg

2-(Acetylthio)acetic acid, 97%, 5g

Tert-butyl (S)-4-hydroxyazepane-1-carboxylate, 95+%, 250mg